{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:22:06Z","timestamp":1758633726951,"version":"3.40.4"},"reference-count":23,"publisher":"Knowledge E DMCC","issue":"4","content-domain":{"domain":["knepublishing.com"],"crossmark-restriction":true},"short-container-title":["JOVR"],"abstract":"<jats:p>Purpose: To evaluate the efficacy, safety, and steroid-sparing effect of topical cyclosporine A (Cs A) 0.05% in patients with moderate to severe steroid dependent vernal keratoconjunctivitis (VKC).\r\nMethods: A prospective, comparative, placebo controlled study was carried out on 68 VKC patients, with 34 patients treated with topical Cs A 0.05% and the remaining 34 with topical carboxymethyl cellulose 0.5% (placebo). Both groups also received topical loteprednol etabonate 0.5%. Symptom (itching, photophobia, tearing, and discharge) score, sign (tarsal and limbal papillae, corneal involvement, and conjunctival hyperemia) score, and drug score (steroid drop usage\/day\/eye) were recorded at baseline and each followup visit. The intraocular pressure (IOP) measurement and evaluation of any ocular side effects were carried out.\r\nResults: Significant reduction in symptom score and sign score was seen in both groups. Cs A group significantly showed more reduction in symptom (P &lt; 0.0001 in all follow-up visits) and sign (P &lt; 0.0001 in all follow-up visits) scores compared to the placebo group. At day 7, mean steroid usage reduced from 4 to 3.44 \u00b1 0.5 and 3.79 \u00b1 0.4 in Cs A and placebo groups, respectively (P &lt; 0.0001). Steroid drops completely stopped in 21 patients at day 60 in the Cs A group compared to none in the placebo group. No significant rise in IOP or any side effects were noted in either group.\r\nConclusion: Topical Cs A 0.05% is effective and safe in patients with moderate to severe VKC with good steroid-sparing effect.<\/jats:p>","DOI":"10.18502\/jovr.v14i4.5439","type":"journal-article","created":{"date-parts":[[2019,10,27]],"date-time":"2019-10-27T07:45:08Z","timestamp":1572162308000},"page":"412-418","update-policy":"https:\/\/doi.org\/10.18502\/knecrossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children"],"prefix":"10.18502","volume":"14","author":[{"given":"Arkendu","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4617-7832","authenticated-orcid":false,"given":"Sabyasachi","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Kumar Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7770","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"key":"20625","doi-asserted-by":"crossref","unstructured":"Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res 2002;21:319\u2013339.","DOI":"10.1016\/S1350-9462(02)00006-X"},{"key":"20626","doi-asserted-by":"crossref","unstructured":"Leonardi A, Secchi AG. Vernal keratoconjunctivitis. Int Ophthalmol Clin 2003;43:41\u201358.","DOI":"10.1097\/00004397-200343010-00007"},{"key":"20627","doi-asserted-by":"crossref","unstructured":"Vichyanond P, Pacharn P, Pleyer U, Leonardi A. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol 2014;25:314\u2013322.","DOI":"10.1111\/pai.12197"},{"key":"20628","doi-asserted-by":"crossref","unstructured":"Ozlem EY, Nihal DU. Efficacy and safety of topical Cyclosporine A 0.05% in vernal keratoconjunctivitis. Singapore Med J 2016;57:507\u2013510.","DOI":"10.11622\/smedj.2015161"},{"key":"20629","doi-asserted-by":"crossref","unstructured":"Leonardi A. Management of Vernal keratoconjunctivitis. Ophthalmol Ther 2013;2:73\u201388.","DOI":"10.1007\/s40123-013-0019-y"},{"key":"20630","doi-asserted-by":"crossref","unstructured":"Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers. Surv Ophthalmol 1986;30:229\u2013244.","DOI":"10.1016\/0039-6257(86)90119-0"},{"key":"20631","doi-asserted-by":"crossref","unstructured":"Gokhale NS. Systematic approach to managing vernal keratoconjunctivitis in clinical practice: severity grading system and a treatment algorithm. Indian J Ophthalmol 2016;64:145\u2013148.","DOI":"10.4103\/0301-4738.179727"},{"key":"20632","doi-asserted-by":"crossref","unstructured":"McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33\u201355.","DOI":"10.2165\/00002018-200225010-00004"},{"key":"20633","doi-asserted-by":"crossref","unstructured":"Oner V, Turkeu FM, Tas M, Iscan Y. Topical loteprednol etabonate 0.5% for treatment of vernal keratoconjunctivitis: efficacy and safety. Jpn J Ophthalmol 2012;56:312\u2013 318.","DOI":"10.1007\/s10384-012-0152-5"},{"key":"20634","unstructured":"Elia\u00e7\u0131k M, Erdo\u011fan F, Bayramlar H, Karaman S, G\u00fclk\u0131l\u0131k G. Comparison of efficacy and safety of Loteprednol etabonate 0.5% versus fluorometholone acetate 0.1% for the treatment of vernal keratoconjunctivitis in pediatric subjects. Nobel Med 2014;11:76\u201382."},{"key":"20635","doi-asserted-by":"crossref","unstructured":"Wu LQ, Chen X, Lu H, Cheng JW, Wei RL. Loteprednol etabonate in the treatment of allergic conjunctivitis: a meta-analysis. Curr Med Res Opin 2015;31:1509\u20131518.","DOI":"10.1185\/03007995.2015.1058250"},{"key":"20636","doi-asserted-by":"crossref","unstructured":"Fukushima A, Yamaguchi T, Ishida W, Fukata K, Liu FT, Ueno H. Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions. Clin Exp Ophthalmol 2006;34:347\u2013353.","DOI":"10.1111\/j.1442-9071.2006.01221.x"},{"key":"20637","doi-asserted-by":"crossref","unstructured":"Kari O, Saari KM. Updates in the treatment of ocular allergies. J Asthma Allergy 2010;3:149\u2013158. 14. Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006;90:461\u2013 464.","DOI":"10.1136\/bjo.2005.082461"},{"key":"20638","doi-asserted-by":"crossref","unstructured":"Tatlipinar S, Akpek EK. Topical cyclosporin in the treatment of ocular surface disorders. Br J Ophthalmol 2005;89:1363\u20131367.","DOI":"10.1136\/bjo.2005.070888"},{"key":"20639","doi-asserted-by":"crossref","unstructured":"Baiza-Duran LM, Gonz\u00e1lez-Villegas AC, Contreras-Rubio Y, Juarez-Echenique JC, Vizzuett-Lopez IV, Suarez- Sanchez R, et al. Safety and efficacy of topical 0.1% and 0.05% cyclosporine A in an aqueous solution in steroiddependent vernal keratoconjunctivitis in a population of Mexican children. J Clin Exp Ophthalmol 2010;1:115. doi: 10.4172\/2155-9570.1000115","DOI":"10.4172\/2155-9570.1000115"},{"key":"20640","doi-asserted-by":"crossref","unstructured":"Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S. A randomized placebo-controlled trial of topical cyclosporine A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 1998;105:1715\u20131720.","DOI":"10.1016\/S0161-6420(98)99043-1"},{"key":"20641","doi-asserted-by":"crossref","unstructured":"Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002;89:298\u2013303.","DOI":"10.1016\/S1081-1206(10)61958-8"},{"key":"20642","doi-asserted-by":"crossref","unstructured":"Spadavecchia L, Fanelli P, Tesse R, Brunetti L, Cardinale F, Bellizzi M, et al. Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol 2006;17:527\u2013532.","DOI":"10.1111\/j.1399-3038.2006.00427.x"},{"key":"20643","doi-asserted-by":"crossref","unstructured":"Keklikci U, Soker SI, Sakalar YB, Unlu K, Ozekinci S, Tunik S. Efficacy of topical cyclosporine A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. Jpn J Ophthalmol 2008;52:357\u2013362.","DOI":"10.1007\/s10384-008-0577-z"},{"key":"20644","doi-asserted-by":"crossref","unstructured":"Akpek EK, Dart JK, Watson S, Christen W, Dursun D, Yoo S, et al. A randomized trial of topical cyclosporine 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004;111:476\u2013482.","DOI":"10.1016\/j.ophtha.2003.05.035"},{"key":"20645","doi-asserted-by":"crossref","unstructured":"De Smedt S, Nkurikiye J, Fonteyne Y, Tuft S, De Bacquer D, Gilbert C, et al. Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, central Africa: a prospective, randomised, double-masked, controlled clinical trial. Br J Ophthalmol 2012;96:323\u2013328.","DOI":"10.1136\/bjophthalmol-2011-300415"},{"key":"20646","doi-asserted-by":"crossref","unstructured":"Wu MM, Yau GS, Lee JW, Wong AL, Tam VT, Yuen CY. Retrospective review on the use of topical cyclosporin a 0.05% for pediatric allergic conjunctivitis in Hong Kong Chinese. Scient World J 2014;2014:396987. doi: 10.1155\/2014\/396987","DOI":"10.1155\/2014\/396987"},{"key":"20647","doi-asserted-by":"crossref","unstructured":"Keklikci U, Dursun B, Cingu AK. Topical cyclosporin A 0.05 % eye drops in the treatment of vernal keratoconjunctivitis. Randomized placebo-controlled trial. Adv Clin Exp Med 2014;23:455\u2013461.","DOI":"10.17219\/acem\/37145"}],"container-title":["Journal of Ophthalmic and Vision Research"],"original-title":[],"link":[{"URL":"https:\/\/knepublishing.com\/index.php\/JOVR\/article\/download\/5439\/10714","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/knepublishing.com\/index.php\/JOVR\/article\/download\/5439\/10740","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/knepublishing.com\/index.php\/JOVR\/article\/download\/5439\/10714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:05:31Z","timestamp":1744355131000},"score":1,"resource":{"primary":{"URL":"https:\/\/knepublishing.com\/index.php\/JOVR\/article\/view\/5439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,10,24]]}},"URL":"https:\/\/doi.org\/10.18502\/jovr.v14i4.5439","relation":{},"ISSN":["2008-322X","2008-2010"],"issn-type":[{"type":"electronic","value":"2008-322X"},{"type":"print","value":"2008-2010"}],"subject":[],"published":{"date-parts":[[2019,10,24]]}}}